
|Videos|October 10, 2016
How Can Access to PCSK9 Inhibitors be Improved?
Author(s)Lauren Santye, Assistant Editor
Mark Tesell, PharmD, BCPS, clinical consultant pharmacist for UMass Medical School Clinical Pharmacy Services, discusses potential solutions for access to cholesterol lowering drugs to improve.
Advertisement
Mark Tesell, PharmD, BCPS, clinical consultant pharmacist for UMass Medical School Clinical Pharmacy Services, discusses potential solutions for access to cholesterol lowering drugs to improve.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
Enlicitide Meaningfully Lowers LDL-C at 24 Weeks in Patients At Risk for ASCVD Events
3
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
4
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
5


























